期刊文献+

胰腺癌细胞对 5 - Fu和吉西它滨获得性耐药后bcl- x_L 和mcl- 1表达的变化(英文) 被引量:1

The expression of bcl-x_L and mcl-1 following acquired chemoresistance in pancreatic cancer cells
下载PDF
导出
摘要 目的 :探讨胰腺癌细胞对 5 Fu和吉西它滨的获得性耐药后bcl xL 和mcl 1表达的变化。方法 :应用SRB方法检测 5 Fu和吉西它滨对胰腺癌细胞株Panc 1,Mia Paca 2和Capan 1的细胞毒性作用 ,应用Westernblot法来检测bcl xL 和mcl 1的蛋白表达水平。结果 :5 Fu和吉西它滨对 3株胰腺癌细胞均产生了细胞毒性作用 ,5 Fu长期作用后 ,Capan 1细胞IC50 上升了 2 .1倍 (P <0 .0 5 )。吉西它滨长期作用后 ,Capan 1细胞IC50 上升了 1.5倍 (P <0 .0 5 )。 5 Fu或吉西它滨长期作用后 ,产生了获得性耐药的胰腺癌细胞bcl xL 和mcl 1表达水平上调。结论 :5 Fu或吉西它滨长期作用后 ,产生了获得性耐药 ,这种耐药与bcl xL 和mcl 1的过度表达相关。 Objective:To study the relationships between the acquired resistance of Gemcitabine and 5 Fu and the expression of bcl x L and mcl 1 in pancreatic cancer cell lines.Methods:The cytotoxic effects of 5 Fu and Gemcitabine in Panc 1,Mia Paca 2 and Capan 1 pancreatic cancer cells were assessed using Sulforhodamine B methods and expression levels of anti apoptotic genes of the bcl x L and mcl 1 were analyzed by Western blot.Results:5 Fu and Gemcitabine displayed cytotoxic effects towards three pancreatic cancer cell lines.After recurrent treatment with 5 Fu,the IC 50 values in Capan 1 cells increased 2.1 fold compared to their parental cells (P<0.05).Following recurrent treatment with Gemcitabine,the IC 50 values in Capan 1 cells increased 1.5 fold (P<0.05).Western blot analysis show that aftter recurrent treatment with 5 Fu and Gemcitabine the expression of bcl x L and mcl 1 upgraded.Conclusion:Overexpression of bcl x L and mcl 1 following recurrent exposure to 5 Fu or Gemcitabine are associaed with the acqurired these drugs
出处 《中国现代普通外科进展》 CAS 2002年第3期156-161,共6页 Chinese Journal of Current Advances in General Surgery
关键词 胰腺癌 5-FU 吉西它滨 BCL-XL MCL-1 耐药性 基因表达 Gene,bcl x L Gene,mcl 1 Drug tolerance Pancreatic neoplasmsi Gene expression
  • 相关文献

参考文献29

  • 1Parker SL,Tong T,Bolden S,WingoPA.Cancer statistics,1997[J].CA Cancer J Clin,1997,47:5-27.
  • 2Gudjonsson B.Cancer of the pancreas.50 years ofsurgery[J].Cancer,1987,60:2284-2303.
  • 3Blaszkowsky L.Treatment of advanced and metastatic pancreatic cancer[J].FrontBiosci,1998,3:E214-225.
  • 4Kollmannsberger C,Peters HD,Fink U.Chemotherapy in advanced pancreaticadenocarcinoma[J].Cancer Treat Rev,1998,24:133-156.
  • 5Ahlgren JD.Chemotherapy for pancreatic carcinoma[J].Cancer,1996,78:654-663.
  • 6Lund B,Kristjansen PE,Hansen HH.Clinical and preclinical activity of2',2'-difluorodeoxycytidine(gemcitabine)[J].Cancer Treat Rev,1993,19:45-55.
  • 7Kaye SB.Gemcitabine:current status of phase Ⅰ and Ⅱ trials[J].J ClinOncol,1994,12:1527-1531.
  • 8Burch PA,Ghosh C,Schroeder G,et al.Phase Ⅱ evaluation of continuous-infusion5-fluorouracil,leucovorin,mitomycin-C,and oraldipyridamole in advanced measurablepancreatic cancer:a North Central Cancer Treatment Group Trial[J].Am J ClinOncol,2000,23:534-537.
  • 9Miyashita T,Reed JC.Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in ahuman leukemia cell line[J].Blood,1993,81:151-157.
  • 10Korsmeyer SJ.Bcl-2initiates a new category of oncogenes:regulators of celldeath[J].Blood,1992,80:879-886.

同被引文献4

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部